Pulmonary hypertension:
Indications for: VENTAVIS
Pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms to improve exercise ability and delay clinical worsening.
Adult Dosage:
Initially 2.5mcg, if tolerated, uptitrate to 5micrograms 6–9 times daily based on tolerability (no more than every 2 hrs); max 45mcg/day. Monitor vital signs while initiating therapy. Hepatic impairment: consider increasing dosing interval (eg, 3–4 hours) between doses.
Children Dosage:
Not recommended.
VENTAVIS Warnings/Precautions:
Do not start therapy if systolic BP <85 mmHg. Discontinue immediately if pulmonary edema occurs (may indicate pulmonary venous hypertension). Bleeding disorders. Avoid contact with skin, eyes, or oral ingestion. COPD. Severe asthma. Acute pulmonary infections. Hepatic or renal impairment. Elderly. Pregnancy. Nursing mothers: not recommended.
VENTAVIS Classification:
Prostacyclin analogue.
VENTAVIS Interactions:
Potentiates hypotensive effect of vasodilators and antihypertensives. May potentiate anticoagulants. Do not mix with other drugs.
Adverse Reactions:
Vasodilation, increased cough, headache, lockjaw, insomnia, GI upset, hypotension, flu syndrome, back pain, abnormal lab tests (eg, increased GGT, alkaline phosphatase), tongue pain, palpitations, syncope, muscle cramps, hemoptysis, pneumonia, CHF, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, kidney failure.
How Supplied:
Single-use ampules—30
